Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Panulisib |
Synonyms | |
Therapy Description |
Panulisib (P7170) inhibits Pi3k, mTOR, Alk, and DNA-PK, resulting in inhibition of cancer cell growth (PMID: 25466244, PMID: 25700704). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Panulisib | P7170|AK15176 | ALK Inhibitor 32 DNA_PK Inhibitor 9 mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | Panulisib (P7170) inhibits Pi3k, mTOR, Alk, and DNA-PK, resulting in inhibition of cancer cell growth (PMID: 25466244, PMID: 25700704). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | prostate cancer | sensitive | Panulisib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Panulisib (P7170) inhibited tumor growth in PTEN null prostate cancer cell xenograft models (PMID: 25700704). | 25700704 |
PIK3CA amp | ovarian cancer | sensitive | Panulisib | Preclinical | Actionable | In a preclinical study, Panulisib (P7170) downregulated mTOR pathway signaling in ovarian cancer cells with amplified PIK3CA (PMID: 25700704). | 25700704 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|